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Background: Environmental lead exposure is a possible causative factor for increased blood pressure and
hypertension, but large studies at low-level exposure are scarce, and results inconsistent.
Objective: We aimed to examine the effects of environmental exposure to lead in a large population-
based sample.
Methods: We assessed associations between blood lead and systolic/diastolic blood pressure and hy-
pertension in 4452 individuals (46–67 years) living in Malmö, Sweden, in 1991–1994. Blood pressure was
measured using a mercury sphygmomanometer after 10 min supine rest. Hypertension was deﬁned as
high systolic (Z140 mmHg) or diastolic (Z90 mmHg) blood pressure and/or current use of anti-
hypertensive medication. Blood lead was calculated from lead in erythrocytes and haematocrit. Multi-
variable associations between blood lead and blood pressure or hypertension were assessed by linear and
logistic regression. Two-thirds of the cohort was re-examined 16 years later.
Results: At baseline, mean blood pressure was 141/87 mmHg, 16% used antihypertensive medication, 63%
had hypertension, and mean blood lead was 28 mg/L. Blood lead in the fourth quartile was associated
with signiﬁcantly higher systolic and diastolic blood pressure (point estimates: 1–2 mmHg) and in-
creased prevalence of hypertension (odds ratio: 1.3, 95% conﬁdence interval: 1.1–1.5) versus the other
quartiles after adjustment for sex, age, smoking, alcohol, waist circumference, and education. Associa-
tions were also signiﬁcant with blood lead as a continuous variable. Blood lead at baseline, having a half-
life of about one month, was not associated with antihypertensive treatment at the 16-year follow-up.
Conclusions: Low-level lead exposure increases blood pressure and may increase the risk of hyperten-
sion.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Inc. This is an open access article u
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Environmental exposure to lead is ubiquitous. This poses a
common public health problem, particularly in terms of effects on
the central nervous system in children. In adults, exposure to lead
has been evaluated as a possible causative factor of increased
blood pressure (BP) or hypertension, in occupationally exposed
individuals as well as in the general population (WHO, 2011; NTP
Monograph on Health Effects of Low-level Lead, 2012). The most
common biomarker of lead exposure is lead in blood (B-Pb);
however, this mainly reﬂects recent exposure, since the half-life of
lead in blood and soft tissue is about a month, while lead in bonender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A. Gambelunghe et al. / Environmental Research 149 (2016) 157–163158is a measure of long-term exposure and body burden (Barbosa
et al., 2005). In adults, 490% of body lead is located in the ske-
leton, and the half-life is about 5 years in trabecular bone and 10–
20 years in cortical bone (EFSA, 2010; Skerfving and Bergdahl,
2015).
Two meta-analyses have been performed regarding lead ex-
posure and increased BP or hypertension. One used lead in bone as
an indicator of lead exposure, (Navas-Acien et al., 2008) and the
other used B-Pb (Nawrot et al., 2002). The strongest association
with BP was seen with lead in bone, but the meta-analysis using
B-Pb as indicator also found a signiﬁcant association between lead
and BP. However, the effect size in the latter case was limited, with
a two-fold increase in B-Pb producing an increase of 1.0 (95%
conﬁdence interval [CI]: 0.5–1.4) mmHg in systolic BP (SBP), and
an increase of 0.6 (95% CI: 0.4–0.8) mmHg in diastolic BP (DBP).
A recent review by the United States of America National
Toxicology Program (NTP) (NTP Monograph on Health Effects of
Low-level Lead, 2012) found that the available epidemiological
studies and animal studies provide sufﬁcient evidence that lead
exposure is associated with increased BP, but not for low-level
exposure (o50 mg/L).
The studies reviewed by the NTP (NTP Monograph on Health
Effects of Low-level Lead, 2012) included only three large (41000
participants) cross-sectional studies, and no prospective study in
adults (apart from pregnant women) with average B-Pb o50 mg/L,
and the results from these were inconsistent. An English study
(Bost et al., 1999) showed an association between B-Pb and dia-
stolic but not systolic BP in men, but no associations in women.
Studies using data from the National Health and Nutritional Ex-
amination Survey (NHANES) III (Den Hond et al., 2002) showed
signiﬁcant associations between B-Pb and SBP in black men and
women, and DBP in black women, but in white men there was a
signiﬁcant decrease in DBP with increasing B-Pb. NHANES data
from 1999 to 2002 showed that the odds ratios (ORs) for hy-
pertension increased with increasing B-Pb, and that the trend was
nearly signiﬁcant in non-Hispanic blacks and Mexican Americans
but not in non-Hispanic whites (Muntner et al., 2005). After the
publication of the NTP review (NTP Monograph on Health Effects
of Low-level Lead, 2012), another study based on NHANES (2003–
2010) found signiﬁcant associations between B-Pb and systolic and
diastolic BP among men and women, although there were no
signiﬁcant associations in white men or women (Hara et al., 2010).
There was no signiﬁcantly increased risk for hypertension in any
group.
The aim of the present study was to examine associations be-
tween lead exposure and BP and hypertension in a large cross-
sectional study from Sweden, in a population-based sample with
on average low (mean o50 mg/L) B-Pb levels. Two-thirds of the
cohort was re-examined after 16 years.2. Methods
2.1. Study population
Our study is based on the cardiovascular cohort in the Malmö
Diet and Cancer Study (MDCS-CC). This cohort includes 6103 in-
dividuals living in Malmö, Sweden, aged 46–67 years, and ex-
amined in 1991–1994 (Rosvall et al., 2000). It is a random sample
of the larger population-based Malmö Diet and Cancer Study
(MDCS) (Berglund et al., 1993). Under the inclusion criterion of
having data available on both B-Pb and BP, 4452 individuals were
eligible for the present study, and 2904 of these (65%) could be re-
examined in 2007–2012. Of those who could not be followed up,
44% had died, while the others were sick or unwilling to attend,
had emigrated, or could not be traced (Rosvall et al., 2015).The study complies with the Declaration of Helsinki. All parti-
cipants provided written informed consent, and the study was
approved by the regional ethics committee.
2.2. Blood pressure and cardiovascular risk factors
The participants completed established self-administered
questionnaires concerning lifestyle, socioeconomic status, health,
and medication, and underwent medical examination (Rosvall
et al., 2000). Blood pressure was measured by a study nurse using
a standard mercury sphygmomanometer with a 14 cm cuff after
supine rest for 10 min at baseline and at follow-up. Hypertension
was deﬁned as an average SBPZ140 mmHg or DBPZ90 mmHg
and/or current use of antihypertensive medication prescribed by a
physician (Mancia et al., 2013).
At baseline, participants were categorized into never, former, or
current smokers. Pack-years of smoking were calculated as the
product of the number of years of smoking and the number of
cigarettes smoked daily, divided by 20. Data on pack-years were
available for 1208 current smokers, 815 ex-smokers, and all non-
smokers (n¼1915), who were given the value of zero (in total
n¼3938). Daily alcohol intake was calculated in grams per day.
Leisure time physical activity was a composite measure of 18 dif-
ferent leisure time activities during the preceding year (Li et al.,
2009). Low physical activity was deﬁned as the lowest quartile of
the summary score. Educational level was classiﬁed as low if
participants had completed less than 12 years of education (i.e.
had not completed secondary education). Height, weight, and
waist circumference were measured, and body mass index (BMI)
was calculated.
2.3. Lead and cadmium analyses
Peripheral blood samples were obtained at baseline by vene-
puncture after overnight fast. In whole blood, lead (Pb) is located
in red blood cells with only marginal levels in plasma (EFSA, 2010;
Skerfving and Bergdahl, 2015). Since an association between cad-
mium (Cd) and hypertension has been described in the literature,
we also analysed Cd, which like Pb is localized in the red blood
cells (Akerstrom et al., 2013). Pb and Cd in whole blood were
calculated from haematocrit and erythrocyte concentrations of Pb
and Cd, respectively, using erythrocytes which had been kept
frozen at 80 °C since the baseline examination. The analysis of
Pb and Cd in erythrocytes was performed by inductively coupled
plasma mass spectrometry operating in the helium collision cell
mode as described previously (Fagerberg et al., 2015). Samples
were diluted 20 times with a basic diluent containing 1-butanol
(2% w/v), ethylenediamine tetraacetic acid (0.05% w/v), Triton
X-100 (0.05% w/v), and ammonium hydroxide (1% w/v). None of
the samples were below the limits of detection, which were
0.16 mg/L for Pb and 0.02 mg/L for Cd. External quality control
samples with a low Pb level (Seronorm Trace Elements Whole
Blood L-1, Lot no. 1103128; Sero AS, Billingstad, Norway) were
included in all analytical rounds (N¼38), and showed satisfactory
results (mean 10.3 mg/L, SD 0.5 mg/L versus recommended limits of
6–14 mg/L). The imprecision (coefﬁcient of variation) was 5.1% for
Pb and 7.1% for Cd, as calculated for 38 duplicate samples of the L-1
quality control sample.
2.4. Data analyses
2.4.1. Cross-sectional analyses
Data were available on BP, smoking, and levels of Pb and Cd in
blood for 4552 individuals. Since we suspected a non-linear effect
of Pb and Cd, B-Pb and B-Cd were classiﬁed in quartiles.
Descriptive statistics were calculated, and BP and prevalence of
Table 2
Systolic blood pressure (SBP), diastolic blood pressure (DBP), and hypertension (HT)
versus blood lead (B-Pb) (quartile 4 versus quartiles 1–3) with and without ad-
justment for other factors.
SBP DBP HT
β coefﬁcient β coefﬁcient OR (95% CI)
(p-value) (p-value) (p-value)
Model
1. B-Pb only (Q4 versus Q1–3) 2.6 2.1 1.4 (1.2–1.6)
o0.001 o0.001 o0.001
2. B-Pb, sex, age, smoking, alcohol,
waist, education
1.8 1.4 1.3 (1.1–1.5)
0.006 o0.001 0.002
3. B-Pb, sex, age, smoking, alcohol,
waist, education, and B-Cd
1.7 1.3 1.3 (1.1–1.5)
0.01 o0.001 0.004
A. Gambelunghe et al. / Environmental Research 149 (2016) 157–163 159hypertension were ﬁrst compared by quartiles of B-Pb. Blood lead
levels were generally low, and so our a priori hypothesis was that
any effect of B-Pb on BP and/or hypertension would have a
threshold and would mainly be found in the highest B-Pb quartile.
Differences in outcomes or in cardiovascular risk factors be-
tween the fourth B-Pb quartile and the other quartiles were tested
using a t-test or a chi-squared test. Associations between single
variables and B-Pb as a continuous variable were assessed with the
Spearman correlation coefﬁcient (rs) or a t-test.
Multivariable associations between B-Pb (in quartiles) and
systolic and diastolic BP were examined using multiple linear re-
gression analysis. Apart from crude analyses (Model 1), we used
two multivariable models: Model 2 included B-Pb, age, and those
variables associated with both B-Pb and blood pressure (sex, al-
cohol intake, smoking habits, waist circumference, and educa-
tional level), while Model 3 also included B-Cd (in quartiles).
Multivariable associations between B-Pb (in quartiles) and hy-
pertension were examined using multiple logistic regression
analysis with the same models as for BP.
In order to assess whether B-Pb was associated with BP at low
levels of B-Pb, we also excluded individuals with the highest B-Pb
in the fourth quartile. In a sensitivity analysis, we replaced B-Pb
with lead in erythrocytes (Ery-Pb) in quartiles. We also repeated
the linear and logistic regression analyses with B-Pb as a con-
tinuous variable using the same models as above for quartiles of
B-Pb. Finally, in Model 3, we assessed a possible associationTable 1
Characteristics of 4452 participants in the cardiovascular cohort of the Malmö Diet and C
or %.
Blood-lead quartile (lg/L)
N All Q1
4452 1113
B-Pb (lg/L) 28 15
(1.5–258) (1.5–19)
Sex (women %) 66 78
Age (years) 57 57
(46–67) (46–67)
Smoking
Never (%) 40 51
Former smokers (%) 34 32
Current smokers (%) 26 17
BMI (kg/m2) 26 26
(16–51) (17–51)
Waist (cm) 83 81
(54–152) (59–152)
SBP (mmHg) 141 140
(98–220) (98–210)
DBP (mmHg) 87 86
(58–130) (60–118)
Hypertension (%) a 63 63
Antihypertensive
medication (%) 16 17
Low education (%) 47 48
Low physical activity (%) 23 23
B-Cd (lg/L) 0.48 0.35
(0.03–5.1) (0.04–4.4)
a Systolic blood pressure Z140 or diastolic blood pressure Z90 or antihypertensivbetween B-Cd and BP and hypertension.
(P-value)s refer to two-tailed tests.
2.4.2. Analyses based on individuals examined at follow-up
Since antihypertensive treatment was common at follow-up
(58%), we used antihypertensive treatment as outcome in the
longitudinal analysis. We also studied hypertension at follow-upancer Study (MDCS-CC) by quartiles (Q1–Q4) of lead in blood (B-Pb). Mean (range)
Q2 Q3 Q4 (P-value)
1113 1113 1113 Q4 versus Q1–3
22 28 47
(19–25) (25–33) (33–258)
66 54 41 o0.001
58 57 57 0.51
(46–67) (46–67) (46–67)
Po0.001
46 35 29
30 38 35
24 27 37
26 26 26 P¼0.34
(17–43) (16–41) (16–43)
82 84 86
(59–134) (54–135) (56–138) po0.001
140 140 143 Po0.001
(98–220) (105–210) (98–210)
86 87 89 Po0.001
(58–126) (60–130) (62–120)
60 49 69 Po0.001
14 16 17 P¼0.28
49 45 44 P¼0.07
24 22 25 P¼0.27
0.42 0.50 0.63 Po0.001
(0.06–4.3) (0.04–4.8) (0.03–5.1)
e medication.
Fig. 1. Panel A: Systolic blood pressure (SBP) with 95% conﬁdence interval versus blood lead in quartiles (Q1–Q4) at baseline, adjusted for sex, age, smoking, alcohol intake,
waist circumference, and educational level. Panel B: Diastolic blood pressure (DBP) with 95% conﬁdence interval versus blood lead in quartiles (Q1–Q4) at baseline, adjusted
as in Panel A. Panel C: Odds ratio (with 95% conﬁdence interval) for hypertension (SBPZ140 mmHg and/or DBPZ90 mmHg and/or current use of antihypertensive
medication) adjusted for covariates as in panel A.
Table 3
Systolic blood pressure (SBP), diastolic blood pressure (DBP), and hypertension (HT)
versus B-Pb, stratiﬁed by sex, age, and smoking. The models are adjusted for sex,
age, smoking, alcohol, waist, and education (Model 2 in Table 2, except for the
stratiﬁcation variable). β coefﬁcients, odds ratios, and (p-value)s refer to the
comparison of quartile 4 versus quartiles 1–3 combined.
SBP DBP HT
β coefﬁcient (p-
value)
β coefﬁcient (p-
value)
OR (95% CI)
Sex (P for interaction) 0.30 0.30 0.60
Men 2.1 (0.02) 1.7 (0.001) 1.2 (0.96–1.5)
Women 1.5 (0.12) 1.1 (0.02) 1.4 (1.1–1.7)
Smoking (P for
interaction)
o0.001 0.10 0.007
Ever-smokers 3.0 (o0.001) 1.6 (o0.001) 1.5 (1.2–1.8)
Never-smokers 0.6 (0.58) 1.1 (0.06) 0.96 (0.7–1.3)
Age (P for interaction) 0.15 0.65 0.04
r57 years 2.4 (o0.001) 1.4 (o0.001) 1.5 (1.2–1.9)
457 years 1.3 (0.17) 1.5 (o0.001) 1.3 (0.9–1.4)
A. Gambelunghe et al. / Environmental Research 149 (2016) 157–163160using the same deﬁnition as for the baseline examination. Multi-
variable associations between B-Pb at baseline and risk of hy-
pertension at follow-up were examined using multiple logistic
regression analysis with Model 2 from the analyses of baseline
data (i.e. B-Pb in quartiles, age, sex, alcohol intake, smoking habits,
waist circumference, and educational level, all at baseline). Since
individuals examined at follow-up were not representative of all
individuals examined at baseline, we also repeated the baseline
analyses for this subgroup (N¼2904).3. Results
3.1. Cross-sectional analyses
At the beginning of the 1990s, the mean blood pressure in this
general population sample aged 46–67 years was 141/87 mmHg
(Table 1). Based on today's criteria (Mancia et al., 2013),hypertension was present in 63% of the sample (68% of the women
and 59% of the men), even though only 16% used antihypertensive
medication. Mean B-Pb was higher in men (32 mg/L) than in wo-
men (25 mg/L).
When the participants were stratiﬁed in B-Pb quartiles, systolic
and diastolic BP were signiﬁcantly higher in the fourth quartile
than in the other three quartiles combined (Table 1). The pre-
valence of hypertension was also higher in the fourth quartile.
Current smoking and high B-Cd were more frequent in the fourth
B-Pb quartile, and the individuals in this quartile also had a ten-
dency toward having higher education.
Multivariable analyses showed that the associations between
B-Pb and BP persisted after adjustment for sex, age, smoking ha-
bits, alcohol intake, waist circumference, and educational level.
The point estimate was 1–2 mmHg increase of SBP and DBP in the
fourth quartile versus the other three quartiles combined (Table 2,
Model 2, and Fig. 1). Additional adjustment for B-Cd changed the
estimates only marginally. There was an association between B-Pb
and prevalence of hypertension with an OR of 1.3 (95% CI: 1.1–1.5)
in the fourth quartile. However, antihypertensive medication (16%)
was not signiﬁcantly associated with B-Pb (OR: 1.1, 95% CI: 0.9–
1.3).
Mean B-Pb was 32 mg/L among current smokers, 28 mg/L among
ex-smokers, and 25 mg/L among never-smokers (Po0.001 for all
comparisons). The corresponding mean levels for B-Cd were 1.06,
0.29, and 0.23 mg/L. In ex-smokers who had quit smoking 420
years before recruitment (N¼484), B-Pb and B-Cd were the same
as in never-smokers. There was a signiﬁcant interaction between
smoking (ever versus never) and B-Pb for both BP and prevalence
of hypertension (Model 2, Table 3). Associations with B-Pb were
statistically signiﬁcant in ever-smokers but not in never-smokers.
In the combined group of never-smokers and ex-smokers who had
quit smoking 420 years before recruitment, the results were si-
milar to those for never-smokers, but the positive association be-
tween B-Pb and DBP was now statistically signiﬁcant (beta
1.2 mmHg, P¼0.01). There was also a tendency towards stronger
associations with B-Pb in participants r57 years compared with
older participants. There were no signiﬁcant gender differences
regarding the associations between B-Pb and BP or hypertension,
and there were no interactions between B-Pb and waist
A. Gambelunghe et al. / Environmental Research 149 (2016) 157–163 161circumference for BP or hypertension.
The association between B-Pb and BP was still signiﬁcant when
B-Pb was treated as a continuous variable in the models; the beta
coefﬁcients for a 20 mg/L increase in B-Pb were 1.2 mmHg for SBP
(P¼0.002) and 1.0 mmHg for DBP (Po0.001). The adjusted
(Model 2) OR for hypertension was 1.1 for a 20 mg/L increase in
B-Pb (P¼0.04).
When repeating all data analyses using lead in erythrocytes
(Ery-Pb) instead of B-Pb, the results were essentially the same
regarding associations between Ery-Pb and BP and hypertension
(data not shown). Results were also unchanged if we included
menopausal status in the adjusted models.
We also repeated the multivariable models for SBP and DBP
after exclusion of all individuals on antihypertensive medication.
The associations with B-Pb were still statistically signiﬁcant, and
the point estimates in Table 2 were similar (data not shown).
In order to assess whether the associations between B-Pb and
BP and hypertension were driven by the individuals with the
highest B-Pb levels (i.e. those in the fourth quartile), the analyses
were repeated excluding individuals with B-Pb 4100 mg/L
(N¼20); the beta coefﬁcients and ORs in Model 2 were essentially
the same, and the associations were still statistically signiﬁcant.
When excluding all individuals with B-Pb 450 mg/L, the beta
coefﬁcient for SBP decreased from 1.8 (Table 2) to 0.8 and was no
longer statistically signiﬁcant. The beta coefﬁcient for DBP de-
creased from 1.4 to 1.0 (P¼0.005), and the OR for hypertension
decreased from 1.3 (Tables 2) to 1.2 (P¼0.048).
There were no associations between B-Cd and BP or hy-
pertension (data not shown).
3.2. Analyses based on individuals examined at follow-up
The mean age of individuals examined at follow-up was 73
years. Their mean age at baseline was 56 years, versus 59 years for
those who could not be examined at follow-up, reﬂecting the
higher risk of dying or drop-out for other reasons in the oldest
individuals. The mean SBP and DBP at follow-up were 143 and
83 mmHg. The mean baseline SBP, DBP, and prevalence of anti-
hypertensive medication were all signiﬁcantly higher (Po0.001)
among individuals who could not be followed up. There was no
increased risk of antihypertensive medication at follow-up in in-
dividuals in the highest B-Pb quartile at baseline (OR: 1.0, 95% CI:
0.8–1.2), and the result was similar (OR: 1.0, 95% CI: 0.7–1.3) if we
included individuals with high BP at follow-up but no anti-
hypertensive medication.
The analysis of baseline data for this sub-cohort showed
weaker associations between B-Pb and outcomes at baseline than
in participants lost to follow-up. The point estimate for SBP was
1.5 mmHg increase in the fourth quartile versus the other three
quartiles combined among individuals examined at follow-up, and
2.2 mmHg in individuals lost to follow-up. For DBP, the corre-
sponding ﬁgures were 1.1 mmHg and 2.0 mmHg. The OR for hy-
pertension at baseline was 1.3 (1.04–1.5) among those examined at
follow-up, and 1.4 (1.05–2.0) among those lost to follow-up.4. Discussion
In this population-based study conducted in Sweden in the
1990s, both systolic and diastolic blood pressures were higher in
the fourth quartile of blood lead, even after adjustment for po-
tential confounders such as age, sex, smoking habits, alcohol in-
take, waist circumference, and educational level. The association
with B-Pb was also present for hypertension, with a signiﬁcantly
increased OR of 1.3 in the fourth quartile of B-Pb. Hypertension
was deﬁned as a high blood pressure (SBPZ140 or DBPZ90) atbaseline or treatment for hypertension. Under this deﬁnition, 63%
of individuals had hypertension at baseline, but only 16% of them
used antihypertensive medication.
There was, however, no association between B-Pb at baseline
and antihypertensive medication at follow-up 16 years later. This
is not a surprising ﬁnding, given that blood lead has a half-life of
one month. Bone lead has a much longer half-life, and as pre-
viously summarized, signiﬁcant associations with BP are more
consistently found with bone Pb as a measure of exposure than
with blood Pb (NTP Monograph on Health Effects of Low-level
Lead, 2012). Hence, a reasonable interpretation is that blood lead is
associated with an increase in BP in cross-sectional terms, but not
with the long-term risk of hypertension, given our results, low
B-Pb levels and insufﬁcient representativity of total body burden
of lead exposure. An alternative explanation is that there was a
differential loss of individuals with hypertension caused by lead
exposure, as the majority of the individuals who could not be
followed up had died or were sick, and they had higher BP and a
higher prevalence of hypertension at baseline. This suggestion is
supported by the fact that individuals lost to follow-up had
stronger associations between B-Pb and BP at baseline. At follow-
up, we focused on antihypertensive medication as an outcome,
since we found it less meaningful to test associations between
B-Pb at baseline and BP 16 years later. Regarding antihypertensive
medication, it should be noted that some of these drugs are also
prescribed for conditions other than hypertension.
Our results are in agreement with the results of the meta-
analysis conducted by Nawrot et al. (2002), which demonstrated
an association between BP and B-Pb. However, that meta-analysis
included many studies with much higher B-Pb levels than are
common today, as well as studies of occupationally-exposed
workers.
The present study shows stronger effects of B-Pb on BP and
hypertension than those found in previous studies in the general
population with low B-Pb levels. An analysis of NHANES III (1988–
1994) found an increase in BP with increasing B-Pb in black but
not white participants (Den Hond et al., 2002), and in peri- and
post-menopausal women (Nash et al., 2003). A combined analysis
of NHANES III and NHANES 1999–2002 (Muntner et al., 2005)
showed associations between B-Pb and the risk of hypertension in
Mexican Americans and black participants, but not in white par-
ticipants. The latest NHANES study showed overall associations
between B-Pb and BP, but for white participants this held true only
for DBP, and there were no signiﬁcant associations between B-Pb
and hypertension (Hara et al., 2010). For men, our results are in
agreement with those of Bost et al. (1999); however, the latter
found no signiﬁcant association between BP and B-Pb in women.
Our results are partly in agreement with the NHANES studies, but
we found stronger associations between B-Pb and BP in our
(white) participants, and we also found associations between B-Pb
and hypertension. Aside from those mentioned above, we are
aware of no other large studies incorporating longitudinal follow-
up of individuals with low B-Pb.
The pathophysiology of lead-induced hypertension has been
examined in several studies. Proposed mechanisms, as reviewed
by Vaziri (2008), include dysregulation of the renin-angiotensin-
aldosterone system, direct effects on the endothelium and vascular
smooth muscle, and stimulation of the sympathetic nervous sys-
tem due to elevated production of catecholamines. Several of these
effects may be mediated by oxidative stress, which may be pro-
duced directly by lead ions or by binding of lead to glutathione,
thereby disturbing one of the defence mechanisms against re-
active oxygen species. The effect on endothelium is caused by
binding and inhibition of endothelial nitric oxide synthase, which
decreases nitric oxide production and thus compromises vasodi-
latation (Solenkova et al., 2014). Lead has been shown to promote
A. Gambelunghe et al. / Environmental Research 149 (2016) 157–163162endothelial release of endothelin; to elevate serum levels of nor-
epinephrine, angiotensin-converting enzyme, and thromboxane;
and to decrease production of prostacyclin (Solenkova et al., 2014).
These changes will promote vasoconstriction.
Animal studies provide strong evidence that low-level ex-
posure to lead contributes to onset of hypertension (NTP Mono-
graph on Health Effects of Low-level Lead, 2012). However, ex-
perimental studies show a non-monotonic relationship between
levels of lead exposure and BP, which could partially explain the
inconsistencies observed in human studies (NTP Monograph on
Health Effects of Low-level Lead, 2012).
The mean BP at baseline was high (141/87) according to today's
criteria for hypertension (SBPZ140 or DBPZ90). This is, however,
in agreement with several other studies in Swedish people around
60 years of age in the early 1990s; for example, in 1990, Wil-
helmsen et al. (1997) found a mean BP of 140/87 in men and 141/
84 in women (N¼436). It should be noted, however, that BP
measurements performed on one occasion only may result in
overestimation of BP for some individuals. The reason why only
16% were on antihypertensive treatment is that in the period be-
fore 1991–1994 (baseline for the present study) the criteria for
start of antihypertensive medication in Sweden (and many other
countries) were less strict than today.
The associations between B-Pb and BP were statistically sig-
niﬁcant, and the effect size was small but not negligible. The beta
coefﬁcients for an increase in B-Pb of 20 mg/L were 1.8 and
1.4 mmHg for SBP and DBP respectively, which was equal to the
difference between the 80th and 20th percentiles of the dis-
tribution. For SBP, this was equivalent to an increase of 2 years of
age or 5 cm of waist circumference, while for DBP it was equiva-
lent to an increase of 9 years of age or 6 cm of waist circumference.
In the present study, blood lead was used as indicator of ex-
posure. Although 490% of lead in blood is found in the ery-
throcytes, lead in whole blood is the most commonly used bio-
marker. In adults, the lead pool in blood constitutes less than 1% of
the body burden (EFSA, 2010; Skerfving and Bergdahl, 2015). The
half-life of lead in blood is about one month, but there is a con-
tinuous exchange between lead in erythrocytes, plasma, and the
skeleton (Skerfving and Bergdahl, 2015), and so B-Pb reﬂects not
only recent exposure, but partly also the body burden. It is
therefore to be expected that a long-term effect of lead exposure
on blood pressure should be more easily demonstrated in studies
using bone lead compared to studies using blood lead as exposure
indicator (Navas-Acien et al., 2008).
It is not clear from previous studies whether there is a
threshold for associations between B-Pb and BP. The associations
between lead and BP were found in the fourth quartile, and the
mean B-Pb in this group was 47 mg/L. The sensitivity analyses
suggest that if there is a threshold, it is below 50 mg/L.
Blood lead levels have decreased over time in Sweden, as in
most countries. The fact that there was no association between age
and B-Pb in the present study indicates that ongoing exposure was
more important for B-Pb levels than a slow mobilization of lead
from bone. However, the age distribution was relatively narrow;
all individuals were 47–67 years of age. The association between
B-Pb and BP seemed slightly weaker among individuals above the
median age (57 years), which might reﬂect the increasing im-
portance of other factors, overshadowing a possible impact of lead
exposure. The fact that B-Pb has decreased over time is important
for evaluation of the exposure-response relationship. Time trends
for B-Pb in children in a city close to the city of the present study
showed a decrease from about 42 mg/L in 1983 to 23 mg/L in 1993.
Mean B-Pb levels were 30–50 mg/L in Swedish adults in the 1980s
(Elinder et al., 1986; Vahter et al., 1991). Thus, if there is a lasting
effect of B-Pb on BP, the associations found in the present study
could reﬂect previous higher exposure levels.It is well known that smoking causes slightly higher B-Pb levels
(Skerfving and Bergdahl, 2015). The association between hy-
pertension and B-Pb was signiﬁcant only among smokers. Smokers
on average have more atherosclerosis and stiffer blood vessels
than non-smokers, which may make them more sensitive to the
effects of lead on BP. However, in the NHANES III study no sig-
niﬁcant interaction was found between smoking and lead re-
garding the association with BP (Nash et al., 2003). Ever-smokers
had higher SBP and DBP than never-smokers, but there was no
association between smoking and risk of hypertension. The asso-
ciation between smoking and BP is complex (Omvik, 1996). BP
increases immediately during smoking, due to the effect of nico-
tine, but when measured in smoking-free intervals, it is often
lower, and it usually increases after smoking cessation (Omvik,
1996; Janzon et al., 2004).
We found no signiﬁcant interaction with sex. Previous studies
of low-level lead exposure have shown mixed results regarding
possible differences between men and women (Bost et al., 1999;
Den Hond et al., 2002; Nash et al., 2003; Muntner et al., 2005;
Hara et al., 2010).
There was no association between B-Cd and either BP or hy-
pertension. Previous studies have not been consistent; however, a
meta-analysis suggested a positive association between blood
cadmium and BP in women, but no such association for urinary
cadmium, and none between cadmium exposure and hyperten-
sion (Gallagher and Meliker, 2010).
The present population-based study is one of the few studies
including a large population with low B-Pb levels. A limitation is
that we did not adjust for family history of hypertension, sodium
intake and kidney function, which are potential confounders. Al-
though the cross-sectional design does not allow causal inference,
the signiﬁcant associations between B-Pb and BP are in agreement
with previous studies at higher lead levels, several of which had a
prospective design. We therefore ﬁnd it likely that the associations
are also causal at these low levels of B-Pb.
In conclusion, the present study suggests that blood lead levels
as low as 20–30 mg/L increase blood pressure and possibly also the
risk of hypertension. Continued efforts to reduce lead exposure are
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